In releasing two draft guidances Thursday on shared risk evaluation and mitigation strategies (REMS), the FDA took aim at another shenanigan some brand drug companies have used to delay competition. The guidances, which discuss the development of a shared system REMS and waivers for the single, shared REMS requirement, are being touted as a way to enhance competition, one of the pillars in the administration's recently announced blueprint to reduce drug prices.